Enhanced Cancer Vaccine Effectiveness with NKTR-214, a CD122-Biased Cytokine
|
|
- Andra Bennett
- 6 years ago
- Views:
Transcription
1 Enhanced Cancer Vaccine Effectiveness with NKTR-214, a CD122-Biased Cytokine Jonathan Zalevsky SVP, Biology and Preclinical Development Nektar Therapeutics SMI Cancer Vaccines, September 2017
2 Nektar Therapeutics San Francisco, CA Huntsville, AL Hyderabad, India 100,000-sq.ft. State-of-the-Art R&D Center 114,000-sq.ft. Manufacturing Facility 88,000-sq.ft. R&D Support Facility Biopharmaceutical company leveraging polymer conjugation technologies to develop new therapies in multiple disease areas Strong heritage of partnership with top biopharma companies ~ 450 employees R&D Center and Headquarters in San Francisco, CA Pharmaceutical Development & Manufacturing in Huntsville, AL R&D support in Hyderabad, India 2
3 Evolution of Nektar s Polymer Conjugation Technology R&D Small molecule NKTR-181 Hepatitis C 2002 Neutropenia Hepatitis C Large Molecule Half-life Extension Acromegaly Chronic kidney disease anemia Wet macular degeneration Crohn s Concentration in Diseased Tissue Opioid induced constipation 2015 Hemophilia A Small Molecule Compartmental Distribution NKTR-262 Biologics NKTR-214 NKTR-255 NKTR-358 Bias Receptor Activity 3
4 Overview An introduction to IO research at Nektar NKTR-214 CD122 biased agonist based on PEG-conjugation of IL-2 Combination of NKTR pmel-1 Melanoma Vaccine pmel-1 cell expansion and functional activation in the tumor microenvironment 4
5 The Immunity Cycle and Multiple Points of Intervention for I-O Therapies 4. Trafficking of T cells to tumor 3. Priming and activation 5. Infiltration of T cells into tumors 2. Cancer antigen presentation 6. Recognition of cancer cells by T cells Source: Oncology Meets Immunology: The Cancer-Immunity Cycle Chen and Mellman Immunity, Volume 39, Issue 1, Release of cancer cell antigens 7. Killing of cancer cells 5
6 Nektar s Immuno-Oncology Strategy to Create Therapies that Cover the Immunity Cycle 4. Trafficking of T cells to tumor (CTLs) Target as many steps as possible in the cycle with as few therapies as possible 3. Priming and activation (APCs & T cells) 2. Cancer antigen presentation (dendritic cells/apcs) 5. Infiltration of T cells into tumors (CTLs, endothelial cells) 6. Recognition of cancer cells by t cells (CTLs, cancer cells) Therapies need to be accessible as medicines 1. Release of cancer cell antigens (cancer cell death) 7. Killing of cancer cells (immune and cancer cells) 6
7 Nektar s Immuno-Oncology Strategy to Create Therapies that Cover the Immunity Cycle 4. Trafficking of T cells to tumor (CTLs) NKTR-214 (CD122 Agonist) Target as many steps as possible in the cycle with as few therapies as possible 3. Priming and activation (APCs & T cells) 2. Cancer antigen presentation (dendritic cells/apcs) Prime, Proliferate, Activate & Increase Tumor-Infiltrating Lymphocytes (TILs), Increase PD-1 expression 5. Infiltration of T cells into tumors (CTLs, endothelial cells) 6. Recognition of cancer cells by t cells (CTLs, cancer cells) Therapies need to be accessible as medicines 1. Release of cancer cell antigens (cancer cell death) 7. Killing of cancer cells (immune and cancer cells) 7
8 NKTR-214: Biasing Action to CD 122, or IL-2R Beta, to Stimulate T-Cell Production Biases signaling to favor the CD122 Receptor (IL- 2Rβγ complex) NKTR-214 Eliminates overactivation of IL-2 pathway that results in serious safety issues CTLs CD8+ T-Cells and NK Cells T regs CD4+ Regulatory T-Cells Achieves antibody-like dosing schedule in outpatient setting Stimulates Immune Response to Kill Tumor Cells Down-Regulates Proliferation of CD8+ T-cells and Suppresses Immune Response 8
9 NKTR-214 Is A CD122-biased Cytokine, Designed To Improve Efficacy And Mitigate Toxicity of the IL-2 Pathway IL-2 Structural model of IL-2 docked with IL-2Rαβγ IL-2Rα (CD25) NKTR-214 High molecular weight hydrolyzable polymers located at strategic sites IL-2Rβ (CD122) IL-2: purple IL-2Rβ: cyan IL-2Rα: blue IL-2Rγ: green IL-2Rγ (CD132) IL-2 cytokine core rhil-2, same amino acid sequence as clinically validated molecule (aldesleukin) 9
10 NKTR-214: Biased Signaling And Prodrug Design To Improve Risk/Benefit Profile NKTR-214 (essentially inactive) % Phospho-STAT5 Charych, D., et al. AACR 2013, Abstract #482 10
11 NKTR-214: Biased Signaling And Prodrug Design To Improve Risk/Benefit Profile NKTR-214 (essentially inactive) Active Species (Biased signaling, increased potency with fewer PEGs) % Phospho-STAT5 Charych, D., et al. AACR 2013, Abstract #482 11
12 NKTR-214: Biased Signaling And Prodrug Design To Improve Risk/Benefit Profile NKTR-214 (essentially inactive) Active Species (Biased signaling, increased potency with fewer PEGs) % Phospho-STAT5 Charych, D., et al. AACR 2013, Abstract #482 12
13 NKTR-214: Biased Signaling And Prodrug Design To Improve Risk/Benefit Profile NKTR-214 (essentially inactive) Active Species (Biased signaling, increased potency with fewer PEGs) % Phospho-STAT5 Charych, D., et al. AACR 2013, Abstract #482 13
14 NKTR-214 Mechanism of Action Delivers a Controlled and Biased Signal to the IL-2 Pathway In mice, a single dose of NKTR-214 gradually builds and sustains pstat5 levels through seven days postdose. In contrast, IL-2 produces a rapid burst of pstat that declines four hours post-dose. pstat5 is a biomarker of IL-2 receptor target engagement. pstat5= signal transducer and activator of transcription 5 p=phosphorylated (activated) Charych, D., et al. AACR 2013, Abstract #482 C57BL/6 mice were treated with either one dose of NKTR-214 (blue) or aldesleukin (red); blood samples were collected at various time points postdose. pstat5 in peripheral blood CD3+ T cells was assessed using flow cytometry. Top graph is an inset showing the 0-4 hour time period. Bottom graph shows the full 10 day time course of the experiment. Histograms on right depict pstat5 MFI for IL-2 (red) and NKTR-214 (blue) 14
15 NKTR-214 Increases The Quality And Quantity Of The T-cell Response in Mice Mouse melanoma model CD8/Treg ratio * * treatment duration Total CD8 / Treg ratio Days > 400-fold increased ratio of CD8 to Treg cells B16F10 melanoma, C57Bl/6 mice; N=9-12/group NKTR-214, 2mg/kg i.v. q9dx3; Aldesleukin, 3mg/kg i.p. bidx5, 2 cycles *, p<0.05, ANOVA with Tukey s post-test (left) or Log-Rank (right) w.r.t. vehicle, p<0.05, Student s T-test (left) or Log-Rank (right) w.r.t. Aldesleukin 15
16 NKTR-214 Selectively Grows T Cells, NK Cells in Tumor Microenvironment in Cancer Patients Analysis of T cell Populations in Tumor CD8 Tregs NKTR-214 drives immune activation in the tumor Increase in total T cells, NK and CD8 T cells No increase in Tregs Increase in PD-1 positive CD8 T cells Increase in newly proliferating CD8 T cells Activation and expression of anti-tumor genes Change in T cell clonality in the tumor Fold change expressed as Week 3 / predose Shown are results from N=10 patients 16
17 Nektar s Immuno-Oncology Strategy to Create Therapies that Cover the Immunity Cycle 4. Trafficking of T cells to tumor (CTLs) NKTR-214 (CD122 Agonist) 3. Priming and activation (APCs & T cells) Prime, Proliferate, Activate & Increase Tumor-Infiltrating Lymphocytes (TILs), Increase PD-1 expression 5. Infiltration of T cells into tumors (CTLs, endothelial cells) 2. Cancer antigen presentation (dendritic cells/apcs) Checkpoint Inhibitors 6. Recognition of cancer cells by t cells (CTLs, cancer cells) 1. Release of cancer cell antigens (cancer cell death) 7. Killing of cancer cells (immune and cancer cells) 17
18 NKTR-214: Combination With Anti-PD-1 Consistently Produces Durable Responses in Mice Long-term survival Colon Cancer Model Long-term survival Breast Cancer Model 100 * NKTR Anti PD Vehicle Anti-CTLA-4 Anti PD-1 Anti CTLA-4 + Anti PD-1 * * NKTR anti-pd-1 NKTR Days anti-ctla-4 + anti-pd Days NKTR anti-pd-1 is superior to anti-ctla-4 + anti-pd-1 CT26 colon carcinoma, Balb/c mice, N=10/group Anti-CTLA-4, 100µg i.p., twice-weekly; Anti-PD-1, 200µg i.p., twice weekly NKTR-214, 0.8mg/kg i.v. q9dx3 *, p<0.05, ANOVA with Tukey s post-test (left) or Log-Rank (right) w.r.t. vehicle EMT6 breast carcinoma, Balb/c mice, N=10/group Anti-CTLA-4, 100µg i.p., twice-weekly; Anti-PD-1, 200µg i.p., twice weekly NKTR-214, 0.8mg/kg i.v. q9dx3 *, p<0.05, ANOVA with Tukey s post-test (left) or Log-Rank (right) w.r.t. vehicle 18
19 NKTR-214 Drives Greater T-cell Expansion And T-Cell Clonality in Mice NKTR apd-1 ImmunoSeq Data (in collaboration with Adaptive Biotechnologies) NKTR apd Days Mean Tumor Volume (mm 3 ) NKTR actla4 actla4 + apd-1 NKTR actla4 NKTR Days actla4 + apd-1 Vehicle actla-4 apd-1 19
20 Harnessing the IL-2 Pathway the Right Way to Increase TILs Prodrug (inactive) Prodrug design to enable safe, outpatient dosing Q2w or Q3w Active cytokine species bias signaling through the heterodimeric IL-2 receptor pathway (IL- 2Rβγ) Biased and sustained signaling to preferentially activate and expand effector CD8+ T and NK cells over Tregs in the tumor microenvironment Currently in multiple clinical trials NKTR checkpoint Combo with nivolumab: 14 tumor types Combo with pembrolizumab in 2 tumors Combo with atezolizumab in 2 tumors Other NKTR-214 combination trials to begin
21 Nektar s Immuno-Oncology Strategy to Create Therapies that Cover the Immunity Cycle 4. Trafficking of T cells to tumor (CTLs) NKTR-214 (CD122 Agonist) Target as many steps as possible in the cycle with as few therapies as possible 3. Priming and activation (APCs & T cells) 2. Cancer antigen presentation (dendritic cells/apcs) Prime, Proliferate, Activate & Increase Tumor-Infiltrating Lymphocytes (TILs), Increase PD-1 expression Vaccine Model Provide Antigens Activate Dendritic Cell Response 1. Release of cancer cell antigens (cancer cell death) 7. Killing of cancer cells (immune and cancer cells) 5. Infiltration of T cells into tumors (CTLs, endothelial cells) 6. Recognition of cancer cells by t cells (CTLs, cancer cells) Checkpoint Inhibitors Therapies need to be accessible as medicines 21
22 Melanoma Vaccine Mouse Model to Study NKTR-214 Pmel-1 cancer vaccine developed by Overwijk and Rosenberg Pmel-1 cells adoptive transfer + peptide vaccination for killing B16F10 tumors IL-2 is essential for driving anti-tumor pmel-1 response Vaccine Vaccine + IL-2 Pmel-1 are genetically marked killer T cells Easy to track in tumor and blood Responsive to anti-melanoma vaccine Kill melanoma cells Use model to study effect of NKTR-214 o o o o o Overwijk et al. JEM 2003 Adoptive transfer of gp100-specific Pmel-1 cells Gp100 peptide (50 ug/mouse)-l-tyr (adjuvant) anti CD40 (50 ug/mouse) TLR-7 agonist (Imiquimod- 5 mice/pack) Recombinant IL-2 (100,000 IU X 5 doses_ Day 0, D1 and D2) or NKTR-214 (0.2mg/kg) 22
23 Evaluation of NKTR-214 in Pmel-1 Vaccine Model 1. No treatment 2. Aldesleukin 3. NKTR Vaccine 5. Vaccine + Aldesleukin (IL-2) 6. Vaccine + NKTR-214 Pmel-1 Cell Transfer Vaccine = gp100 peptide + anti-cd40 + TLR-7 agonist Aldesleukin (IL-2) 100,00 IU b.i.d_d0,d1,d2_q8d NKTR mg/kg_q8d Collaboration with Meenu Sharma, Willem Overwijk Laboratory, MD Anderson Cancer Center 23
24 NKTR-214 More Effective that Aldesleukin to Delay Tumor Growth in Mouse Melanoma Vaccine Model M. Sharma, Willem Overwijk Laboratory, MD Anderson Cancer Center 24
25 NKTR-214 Promotes Massive Pmel-1 Cell Expansion After Vaccination p= <0.001 NKTR-214-vaccine significantly enhanced Pmel-1 T cell response as compared to Aldesleukin-vaccine M. Sharma, Willem Overwijk Laboratory, MD Anderson Cancer Center 25
26 NKTR-214 Vaccine Combination Superior to Aldesleukin for Pmel-1 CD8 T Cell Expansion in Tumor and Spleen Number of Thy1.1+ CD8 T cells / gram of tumor Untreated Vaccine Vaccine + Aldesleukin Vaccine + NKTR-214 Tumor *** 0 D3 D5 D7 D10 Days after vaccination M. Sharma, Willem Overwijk Laboratory, MD Anderson Cancer Center Untreated Vaccine Vaccine + Aldesleukin Vaccine + NKTR-214 Number of Thy1.1+ CD8 T cells /Spleen No Tx Vaccine Vaccine + Aldesleukin Untreated Vaccine + NKTR-214 Vaccine Vaccine + Aldesleukin Vaccine + NKTR-214 *** *** Spleen *** 0 D3 D5 D7 D10 Days after vaccination 26
27 NKTR-214 Promotes Higher Pmel-1/Treg Ratio than Aldesleukin in Tumor and Spleen ure 5 Day 3 No Treatment Vaccine Vaccine + Aldesleukin Vaccine +NKTR-214 B Day 3 Day 5 Day 5 Day 7 Day 7 Day 10 Day Pmel-1/Tregs (Tumor) Pmel-1/Tregs (Spleen) M. Sharma, Willem Overwijk Laboratory, MD Anderson Cancer Center 27
28 NKTR-214 Preferentially Drives Pmel-1 Proliferation Day 7 As compared to Vaccine alone and aldesleukin-vaccine combination, NKTR-vaccine treatment significantly maintained higher proliferation of Pmel-1 T cells and lower proliferation of Tregs in tumor as well as in spleen M. Sharma, Willem Overwijk Laboratory, MD Anderson Cancer Center 28
29 NKTR-214 Preferentially Promotes Pmel-1 Survival Day 7 In tumor, addition of NKTR-214 to vaccine reduced annexin V expression on Pmel-1 and enhanced it on Tregs though no significant change was exhibited in Aldesleukin-Vaccine treatment group In contrast to tumor, Annexin V expression in spleen was reduced on both Pmel-1 T cells and Tregs, in NKTR-vaccine group as compared to vaccine alone M. Sharma, Willem Overwijk Laboratory, MD Anderson Cancer Center 29
30 Summary and Conclusions NKTR-214 is a CD122-biased agonist that effectively activates the IL-2 receptor pathway in preclinical and clinical settings Addition of NKTR-214 to peptide vaccine drives enhanced Pmel-1 T cells in tumor as well as in spleen NKTR-214 is better than Aldesleukin in stably maintaining high CD8+ (Pmel-1 cells) and low Treg numbers in tumor At the peak of Pmel-1 response on day 7, number of Tregs dramatically reduced in tumor of NKTR-vaccine treated group Relative expression of Ki67 and Annexin V indicated that NKTR-vaccine treatment supports proliferation and survival of Pmel-1 T cells in tumor as well as in spleen Reduced proliferation and moderately enhanced apoptosis in intratumoral Tregs, seem to contribute to observed low number of Tregs in tumor of NKTR-vaccine treated mice 30
NKTR-214 plus NKTR-262, a Scientifically-Guided Rational Combination Approach for Immune Oncology
plus NKTR-262, a Scientifically-Guided Rational Combination Approach for Immune Oncology Jonathan Zalevsky SVP, Biology and Preclinical Development Nektar Therapeutics World Preclinical Congress, 2017
More informationEnhanced cancer vaccine effectiveness with NKTR-214, a CD122 biased cytokine
SMi Immuno-Oncology, London Loui Madakamutil, Ph. D Vice President, Head for Discovery Enhanced cancer vaccine effectiveness with NKTR-214, a CD122 biased cytokine Sept 26-27 2018 Nektar Therapeutics San
More informationNKTR-255: Accessing IL-15 Therapeutic Potential through Robust and Sustained Engagement of Innate and Adaptive Immunity
NKTR-255: Accessing IL-15 Therapeutic Potential through Robust and Sustained Engagement of Innate and Adaptive Immunity Peiwen Kuo Scientist, Research Biology Nektar Therapeutics August 31 st, 2018 Emerging
More informationNKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies
NKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies Saul Kivimäe Senior Scientist, Research Biology Nektar Therapeutics NK Cell-Based Cancer Immunotherapy, September 26-27,
More informationJefferies 2017 Global Healthcare Conference. Stephen Doberstein, Ph.D. Senior Vice President & Chief Scientific Officer
Jefferies 2017 Global Healthcare Conference Stephen Doberstein, Ph.D. Senior Vice President & Chief Scientific Officer June 7, 2017 This presentation includes forward-looking statements regarding Nektar
More informationJP Morgan Healthcare Conference. Howard Robin President & CEO January 9, 2018
JP Morgan Healthcare Conference Howard Robin President & CEO January 9, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the timing of the start
More informationJefferies 2016 Healthcare Conference. Howard Robin President & Chief Executive Officer
Jefferies 2016 Healthcare Conference Howard Robin President & Chief Executive Officer June 8, 2016 This presentation includes forward-looking statements regarding Nektar s technology platform, drug candidates,
More informationPiper Jaffray 29 th Annual Healthcare Conference
Piper Jaffray 29 th Annual Healthcare Conference Jonathan Zalevsky, Ph.D. Senior Vice President, Research and Chief Scientific Officer November 28, 2017 This presentation includes forward-looking statements
More informationJohn Langowski, Ph.D. Nektar Therapeutics San Francisco, CA USA
NKTR-38: a selective, first-in-class IL-2 pathway agonist which increases number and suppressive function of regulatory T cells for the treatment of immune inflammatory disorders John Langowski, Ph.D.
More informationJefferies 2018 Healthcare Conference. June 6, 2018
Jefferies 2018 Healthcare Conference z June 6, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the timing of the start and conclusion of ongoing
More information2019 ASCO-SITC. Nektar Therapeutics Investor & Analyst Call. March 1, 2019
Nektar Therapeutics Investor & Analyst Call March 1, 2019 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the timing of the start and conclusion of
More information37th Annual J.P. Morgan Healthcare Conference. Howard Robin President & CEO January 8, 2019
37th Annual J.P. Morgan Healthcare Conference Howard Robin President & CEO January 8, 2019 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the timing
More informationImmune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich
Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationScott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION
Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 11 T-Cell Activation, Differentiation, and Memory Copyright 2013 by W. H. Freeman and
More informationGSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017
GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics
More informationCombining ADCs with Immuno-Oncology Agents
Combining ADCs with Immuno-Oncology Agents Chad May, PhD Senior Director Targeted Immunotherapy Oncology Research Unit, Pfizer 7 th Annual World ADC October 10, 2016 Cancer-Immunity Cycle Innate Immunity
More informationIs Immune Therapy the Holy Grail in Metastatic Kidney Cancer?
Is Immune Therapy the Holy Grail in Metastatic Kidney Cancer? New Frontiers in Urologic Oncology 8-2016 Mayer Fishman, MD PhD Member, Moffitt Cancer Center Department of Genitourinary Oncology Professor,
More informationClinicalTrials.gov Identifier: NCT Adi Diab 1, Nizar Tannir 1, Daniel Cho
Pivot-02: Preliminary safety, efficacy and biomarker results from dose escalation of the Phase 1/2 study of CD-122-biased agonist NKTR-214 plus nivolumab in patients with locally advanced/metastatic melanoma,
More informationImmuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY
More informationDeterminants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco
Determinants of Immunogenicity and Tolerance Abul K. Abbas, MD Department of Pathology University of California San Francisco EIP Symposium Feb 2016 Why do some people respond to therapeutic proteins?
More informationImmuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016
Immuno-Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D February 24, 216 GSK Pipeline Oncology R&D strategy Focusing on 3 areas fundamental to oncology Cancer Epigenetics Long-Term Survival
More informationTumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School
Tumor Immunity and Immunotherapy Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School Lecture Outline Evidence for tumor immunity Types of tumor antigens Generation of anti-tumor
More informationCancer immunotherapy with oncolytic viruses: more than just lysis
Cancer immunotherapy with oncolytic viruses: more than just lysis Dmitriy Zamarin MD PhD Assistant Attending, Immune Therapeutics Center Memorial Sloan-Kettering Cancer Center New York, NY BCAN Think Tank
More informationRXi Pharmaceuticals. Immuno-Oncology World Frontiers Conference. January 23, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals
RXi Pharmaceuticals Immuno-Oncology World Frontiers Conference January 23, 2018 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT
ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS Choompone Sakonwasun, MD (Hons), FRCPT Types of Adaptive Immunity Types of T Cell-mediated Immune Reactions CTLs = cytotoxic T lymphocytes
More informationGlioblastoma and CNS tumors
Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 27 May 2017 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Challenges in immunooncology
More informationCancer Immunotherapy Survey
CHAPTER 8: Cancer Immunotherapy Survey All (N=100) Please classify your organization. Academic lab or center Small biopharmaceutical company Top 20 Pharma Mid-size pharma Diagnostics company Other (please
More informationCombination Immunotherapy Approaches Chemotherapy, Radiation Therapy, and Dual Checkpoint Therapy
Combination Immunotherapy Approaches Chemotherapy, Radiation Therapy, and Dual Checkpoint Therapy Dr. David B. Page Providence Portland Medical Center Earle A. Chiles Research Institute Funding & Disclosures
More information08/02/59. Tumor Immunotherapy. Development of Tumor Vaccines. Types of Tumor Vaccines. Immunotherapy w/ Cytokine Gene-Transfected Tumor Cells
Tumor Immunotherapy Autologous virus Inactivation Inactivated virus Lymphopheresis Culture? Monocyte s Dendritic cells Immunization Autologous vaccine Development of Tumor Vaccines Types of Tumor Vaccines
More informationI farmaci immunoterapici. Stefano Fogli UO Farmacologia Clinica e Farmacogenetica Dipartimento di Medicina Clinica e Sperimentale Università di Pisa
I farmaci immunoterapici Stefano Fogli UO Farmacologia Clinica e Farmacogenetica Dipartimento di Medicina Clinica e Sperimentale Università di Pisa History of Cancer Immunotherapy Discovery of dendritic
More informationCancer Immunotherapy: Active Immunization Approaches
Cancer Immunotherapy: Active Immunization Approaches Willem W. Overwijk, PhD Department of Melanoma Medical Oncology MD Anderson Cancer Center Houston, TX, USA Disclosures No relevant financial relationships
More informationIdentification of novel immune regulators of tumor growth using highthroughput
Identification of novel immune regulators of tumor growth using highthroughput screening in vivo Tom Brennan 1 Five Prime s Unique Platform Tests Nearly Every Extracellular Protein to Identify Protein
More information2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery
C007: Immunology of Melanoma: Mechanisms of Immune Therapies Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los Angeles Biomedical
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationTherapeutic efficacy of MUC1- specific CTL and CD137 costimulation. mammary cancer model. Pinku Mukherjee & Sandra Gendler
Therapeutic efficacy of MUC1- specific CTL and CD137 costimulation in a spontaneous mammary cancer model Pinku Mukherjee & Sandra Gendler Goal of Immunotherapy Boosting the low level anti-tumor immune
More informationThe Galectin-3 Inhibitor GR-MD-02 for Combination Cancer Immunotherapy
The Galectin-3 Inhibitor GR-MD-02 for Combination Cancer Immunotherapy Supplemental Information to Corporate Presentation February 6, 2018 NASDAQ: GALT www.galectintherapeutics.com 2018 2017 Galectin Therapeutics
More informationIMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust
IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent
More informationImmunotherapy: The Newest Treatment Route
Immunotherapy: The Newest Treatment Route IWMF Patient Forum, Phoenix, AZ Madhav Dhodapkar, MD Professor of Medicine and Immunobiology Chief, Section of Hematology Yale University or the Oldest William
More informationSupplementary Figures
Supplementary Figures Supplementary Fig. 1. Surface thiol groups and reduction of activated T cells. (a) Activated CD8 + T-cells have high expression levels of free thiol groups on cell surface proteins.
More informationTumor Immunology: A Primer
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationSITC Nektar Therapeutics Investor & Analyst Call with Melanoma Specialists. November 10, 2018
SITC 2018 Nektar Therapeutics Investor & Analyst Call with Melanoma Specialists November 10, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationGlioblastoma and CNS tumors
Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 1 October 2016 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Immunology in the CNS
More informationIdera Pharmaceuticals
Idera Pharmaceuticals ILLUMINATE-204 Clinical Data Update December 2018 Forward Looking Statements and Other Important Cautions This presentation contains forward-looking statements within the meaning
More informationL1 on PyMT tumor cells but Py117 cells are more responsive to IFN-γ. (A) Flow
A MHCI B PD-L1 Fold expression 8 6 4 2 Fold expression 3 2 1 No tx 1Gy 2Gy IFN Py117 Py117 Supplementary Figure 1. Radiation and IFN-γ enhance MHCI expression and PD- L1 on PyMT tumor cells but Py117 cells
More informationONCOSEC ARMING THE IMMUNE SYSTEM TO FIGHT CANCER NASDAQ: ONCS
ONCOSEC TM ARMING THE IMMUNE SYSTEM TO FIGHT CANCER NASDAQ: ONCS 0 Forward Looking Statements Our commentary and responses to your questions may contain forward looking statements, as described in the
More informationMHC Tetramers and Monomers for Immuno-Oncology and Autoimmunity Drug Discovery
MHC Tetramers and Monomers for Immuno-Oncology and Autoimmunity Drug Discovery Your Partner in Drug Discovery and Research MHC Tetramer Background T-Cell Receptors recognize and bind to complexes composed
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
Award Number: W81XWH-12-1-48 TITLE: Evaluation of the immunologic impact of RAF Inhibitors to Guide Optimal Combination of RAF inhibitors and Immunotherapy for the treatment of Advanced Melanoma PRINCIPAL
More informationRadiation Therapy as an Immunomodulator
Radiation Therapy as an Immunomodulator Yvonne Mowery, MD, PhD February 20, 2017 Tumor/Immune System Balance Kalbasi, JCI 2013 UNC-Duke-NC State-Wake Forest Spring 2017 2 RT Can Shift Balance Toward Elimination
More informationDarwinian selection and Newtonian physics wrapped up in systems biology
Darwinian selection and Newtonian physics wrapped up in systems biology Concept published in 1957* by Macfarland Burnet (1960 Nobel Laureate for the theory of induced immune tolerance, leading to solid
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationAntigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS
1 Antigen Presentation and T Lymphocyte Activation Abul K. Abbas UCSF FOCiS 2 Lecture outline Dendritic cells and antigen presentation The role of the MHC T cell activation Costimulation, the B7:CD28 family
More informationTumor Microenvironment and Immune Suppression
Tumor Microenvironment and Immune Suppression Hassane M. Zarour,, MD Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh Cancer Institute Hallmarks of Cancer: The Next Generation
More informationDisclosure Information. Mary L. Disis
Disclosure Information Mary L. Disis I have the following financial relationships to disclose: Consultant for: VentiRx, Celgene, Emergent, EMD Serono Speaker s Bureau for: N/A Grant/Research support from:
More informationPreclinical Assessment of JTX-2011, An Agonist Antibody Targeting ICOS, Supports Evaluation In ICONIC Clinical Trial
Preclinical Assessment of JTX-211, An Agonist Antibody Targeting ICOS, Supports Evaluation In ICONIC Clinical Trial Jennifer Michaelson, Ph.D. AACR Annual Meeting April 2, 217 Major Symposium Emerging
More informationTolerance 2. Regulatory T cells; why tolerance fails. Abul K. Abbas UCSF. FOCiS
1 Tolerance 2. Regulatory T cells; why tolerance fails Abul K. Abbas UCSF FOCiS 2 Lecture outline Regulatory T cells: functions and clinical relevance Pathogenesis of autoimmunity: why selftolerance fails
More informationT-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:
Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,
More informationT-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:
Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,
More informationImmunotherapy Overview, Rationale, and Role in Clinical Practice
Immunotherapy Overview, Rationale, and Role in Clinical Practice Financial Disclosure Bradi L. Frei, PharmD, BCOP, BCPS has no relevant financial relationships with commercial interests to disclose. OBJECTIVES
More informationGBR 1302: EFFECT OF CD3-HER2, A BISPECIFIC T CELL ENGAGER ANTIBODY, IN TRASTUZUMAB-RESISTANT CANCERS
GBR 1302: EFFECT OF CD3-HER2, A BISPECIFIC T CELL ENGAGER ANTIBODY, IN TRASTUZUMAB-RESISTANT CANCERS JONATHAN BACK 1 ; MARTIN WERMKE 2 ; JULIE MACOIN 1 ; AMELIE CROSET 1 ; JOHN KAUH 3 ; VENKATESHWAR REDDY
More informationHarnessing the Immune System to Prevent Cancer: Basic Immunologic Mechanisms
Harnessing the Immune System to Prevent Cancer: Basic Immunologic Mechanisms (the language of immunology) Barbara K. Dunn NCI/Division of Cancer Prevention October 23, 2017 Harnessing the Immune System
More informationEngineered Immune Cells for Cancer Therapy : Current Status and Prospects
When Engineering Meets Immunology Engineered Immune Cells for Cancer Therapy : Current Status and Prospects Yong Taik Lim, Ph.D. Nanomedical Systems Laboratory (http://www.nanomedicalsystems.org) SKKU
More informationSupplementary Materials for
www.sciencetranslationalmedicine.org/cgi/content/full/8/352/352ra110/dc1 Supplementary Materials for Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy
More informationUnderstanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies. Michael A. Curran, Ph.D.
Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies Michael A. Curran, Ph.D. MD Anderson Cancer Center Department of Immunology Disclosures I have research
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationCurrent Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology
Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Overview Melanoma incidence and prevention Approach to surgical management of early melanoma Landscape of Advanced Melanoma Therapy
More informationDISCLOSURES. Roche/MSD-Merck/Celgene: Research Funding
DISCLOSURES Roche/MSD-Merck/Celgene: Research Funding Roche/Celgene/AstraZeneca/Amgen/MSD/Novartis/Sanofi- Aventis/Pierre Fabré: Advisory Board or Consultant No conflict of interest with respect to this
More informationInnovation in Prevention, Early Detection & Diagnosis of Colorectal Cancer Heidelberg Workshop Session VI, Oncology Pipeline June 6, 2014
Innovation in Prevention, Early Detection & Diagnosis of Colorectal Cancer Heidelberg Workshop Session VI, Oncology Pipeline June 6, 2014 Bernd Mueller MSD Sharp & Dohme, Germany Normal Immune Surveillance:
More informationPresenter Disclosure Information
Phase 1b: Preliminary clinical activity and immune activation for NKTR-262 [TLR 7/8 agonist] plus bempegaldesleukin (NKTR-214) [CD122-biased agonist] in patients (pts) with locally advanced or metastatic
More informationImmune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic
Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers
More informationFifteenth International Kidney Cancer Symposium November 4-5, 2016 Marriott Miami Biscayne Bay, Miami, Florida, USA
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationImmune Checkpoint Inhibitors Drug Combinations: Patients Relevance & Ways Forward
March 25, 2015 Immune Checkpoint Inhibitors Drug Combinations: Patients Relevance & Ways Forward Dr. Alexandre Passioukov p 1 Therapeutic efficacy of agents targeting immune checkpoints Introduction Deep
More informationTMAC Affimer Drug Conjugates
TMAC Affimer Drug Conjugates A novel and proprietary class of immuno-oncology active, dual mode of action drug conjugates PRS 001 Immune-checkpoint Therapies: Improving Patient Response Rates Despite great
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationExploring Immunotherapies: Beyond Checkpoint Inhibitors
Exploring Immunotherapies: Beyond Checkpoint Inhibitors Authored by: Jennifer Dolan Fox, PhD VirtualScopics (Now part of BioTelemetry Research) jennifer_fox@virtualscopics.com +1 585 249 6231 Introduction
More informationTim-3 as a target for tumor immunotherapy
Tim-3 as a target for tumor immunotherapy Ana Carrizosa Anderson Brigham and Women s Hospital Harvard Medical School Disclosures A portion of the work has been performed as part of a sponsored research
More informationFcγRIIIA (CD16)-expressing monocytes mediate the depletion of tumor-infiltrating Tregs via ipilimumab-dependent ADCC in melanoma patients
FcγRIIIA (CD16)-expressing monocytes mediate the depletion of tumor-infiltrating Tregs via ipilimumab-dependent ADCC in melanoma patients Emanuela Romano Department of Oncology University of Lausanne and
More informationImmuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The
More informationCytokines: Interferons, Interleukins and Beyond. Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center
Cytokines: Interferons, Interleukins and Beyond Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center Disclosures Advisory Boards: Bristol-Myers Squibb,Amgen, Novartis, Alkermes, Infinity,
More informationactivation with anti-cd3/cd28 beads and 3d following transduction. Supplemental Figure 2 shows
Supplemental Data Supplemental Figure 1 compares CXCR4 expression in untreated CD8 + T cells, following activation with anti-cd3/cd28 beads and 3d following transduction. Supplemental Figure 2 shows the
More informationImmunotherapy Concept Turned Reality
Authored by: Jennifer Dolan Fox, PhD VirtualScopics Inc. jennifer_fox@virtualscopics.com +1 585 249 6231 Immunotherapy Concept Turned Reality Introduction While using the body s own immune system as a
More informationCurrent Affiliation: NEXT Oncology, San Antonio TX
Safety, Efficacy, and Immune Correlates of Alternative Doses and Schedules of Entinostat Combined With Pembrolizumab in Patients With Advanced Solid Tumors Results From SNDX-275-0141 Phase I Trial Anthony
More informationSTATE OF THE ART 4: Combination Immune Therapy-Chemotherapy. Elizabeth M. Jaffee (JHU) James Yang (NCI) Jared Gollob (Duke) John Kirkwood (UPMI)
STATE OF THE ART 4: Combination Immune Therapy-Chemotherapy Elizabeth M. Jaffee (JHU) James Yang (NCI) Jared Gollob (Duke) John Kirkwood (UPMI) Topics for Consideration What are the rules for integrating
More informationEmerging Targets in Immunotherapy
Emerging Targets in Immunotherapy So Jin Shin, M.D. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea no-0ncology Todays is.. ancer Immunotherapy? nd immunotherapy
More informationImmunotherapy in Lung Cancer - TLR9 as a therapeutic target -
Immunotherapy in Lung Cancer - TLR9 as a therapeutic target - Wilfried Eberhardt,, MD Head of Outpatient Unit, Dept. of Internal Medicine (Cancer Research) West German Cancer Centre Essen University Hospital
More information2/19/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery
F141: Advanced Melanoma: Mechanisms of Immune Therapies beyond Checkpoint blockade Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los
More informationInternational Society of Breast Pathology. Immune Targeting in Breast Cancer. USCAP 2017 Annual Meeting
International Society of Breast Pathology USCAP 2017 Annual Meeting Immune Targeting in Breast Cancer Ashley Cimino-Mathews, MD Assistant Professor of Pathology and Oncology The Johns Hopkins Hospital
More informationSupplemental Table I.
Supplemental Table I Male / Mean ± SEM n Mean ± SEM n Body weight, g 29.2±0.4 17 29.7±0.5 17 Total cholesterol, mg/dl 534.0±30.8 17 561.6±26.1 17 HDL-cholesterol, mg/dl 9.6±0.8 17 10.1±0.7 17 Triglycerides,
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationEmerging Tissue and Serum Markers
Emerging Tissue and Serum Markers for Immune Checkpoint Inhibitors Kyong Hwa Park MD, PhD Medical Oncology Korea University College of Medicine Contents Immune checkpoint inhibitors in clinical practice
More informationEvidence for antigen-driven TCRβ chain convergence in the tumor infiltrating T cell repertoire
Evidence for antigen-driven TCRβ chain convergence in the tumor infiltrating T cell repertoire Geoffrey M. Lowman, PhD Senior Staff Scientist EACR - 02 July 2018 For Research Use Only. Not for use in diagnostic
More informationT Cell Activation. Patricia Fitzgerald-Bocarsly March 18, 2009
T Cell Activation Patricia Fitzgerald-Bocarsly March 18, 2009 Phases of Adaptive Immune Responses Phases of T cell responses IL-2 acts as an autocrine growth factor Fig. 11-11 Clonal Expansion of T cells
More informationRadiation Therapy and Immunotherapy: New Frontiers
Radiation Therapy and Immunotherapy: New Frontiers Nevada Oncology Society Fall Meeting November 16 th, 2017 Anshu K. Jain, MD Radiation Oncologist, Ashland Bellefonte Cancer Center Assistant Clinical
More informationA biomarker-driven approach for the development of the ICOS agonist antibody, JTX-2011 Heather A. Hirsch
A biomarker-driven approach for the development of the ICOS agonist antibody, JTX-2011 Heather A. Hirsch On behalf of Jounce Therapeutics JTX-2011 team Immuno-Oncology Biomarkers: Today s Imperatives for
More informationImmunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells
Immunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells Andrew H. Lichtman, M.D. Ph.D. Department of Pathology Brigham and Women s Hospital and Harvard
More informationThe Enhancement of Anti-Tumor Activities of Selinexor when Combined with Immune Checkpoint Inhibitors
The Enhancement of Anti-Tumor Activities of Selinexor when Combined with Immune Checkpoint Inhibitors Trinayan Kashyap, Karyopharm Therapeutics Yu-Tzu Tai and Kenneth Anderson, Dana Farber Boston Matthew
More informationLAG-3: Validation Of Next Generation Checkpoint Pathways
LAG-3: Validation Of Next Generation Checkpoint Pathways Frédéric Triebel, CO/CMO Immune Checkpoint Modulation & Combination Therapies April 13, 2016 London, UK. 1 AX:PRR; NADAQ:PBMD Notice: Forward Looking
More informationThe Immune System. Innate. Adaptive. - skin, mucosal barriers - complement - neutrophils, NK cells, mast cells, basophils, eosinophils
Objectives - explain the rationale behind cellular adoptive immunotherapy - describe methods of improving cellular adoptive immunotherapy - identify mechanisms of tumor escape from cellular adoptive immunotherapy
More information